<code id='EC7137FA2E'></code><style id='EC7137FA2E'></style>
    • <acronym id='EC7137FA2E'></acronym>
      <center id='EC7137FA2E'><center id='EC7137FA2E'><tfoot id='EC7137FA2E'></tfoot></center><abbr id='EC7137FA2E'><dir id='EC7137FA2E'><tfoot id='EC7137FA2E'></tfoot><noframes id='EC7137FA2E'>

    • <optgroup id='EC7137FA2E'><strike id='EC7137FA2E'><sup id='EC7137FA2E'></sup></strike><code id='EC7137FA2E'></code></optgroup>
        1. <b id='EC7137FA2E'><label id='EC7137FA2E'><select id='EC7137FA2E'><dt id='EC7137FA2E'><span id='EC7137FA2E'></span></dt></select></label></b><u id='EC7137FA2E'></u>
          <i id='EC7137FA2E'><strike id='EC7137FA2E'><tt id='EC7137FA2E'><pre id='EC7137FA2E'></pre></tt></strike></i>

          Home / comprehensive / entertainment

          entertainment


          entertainment

          author:hotspot    Page View:72433
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In